Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

Delayed Quote. Delayed  - 09/23 09:59:48 pm
0.9328 USD   -5.85%
09/22 NAVIDEA BIOPHAR : Achieves $1 Million in Lymphoseek® Commercial Mile..
09/16 NAVIDEA BIOPHAR : Lymphoseek® Receives Positive Opinion in Europe fo..
09/14 NAVIDEA BIOPHAR : to Present at Upcoming Investor Conferences
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
0.9801(c) 0.99(c) 0.9831(c) 0.9908(c) 0.9328(c) Last
1 937 459 1 920 559 1 399 959 6 151 361 1 446 177 Volume
-4.84% +1.01% -0.70% +0.78% -5.85% Change
More quotes
Financials ($)
Sales 2016 24,7 M
EBIT 2016 -4,56 M
Net income 2016 -12,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 35,9 M
EBIT 2017 4,69 M
Net income 2017 -4,41 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 5,87x
Capi. / Sales2017 4,05x
Capitalization 145 M
More Financials
Company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and... 
Sector
Biotechnology & Medical Research
Calendar
09/27 | 04:00pmPresentation
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
09/22 NAVIDEA BIOPHARMACEUTICALS : Achieves $1 Million in Lymphoseek® Commercial Miles..
09/16 NAVIDEA BIOPHARMACEUTICALS : Lymphoseek® Receives Positive Opinion in Europe for..
09/15 NAVIDEA BIOPHARMACEUTICALS : Enters into Letter of Intent with Cardinal Health f..
09/14 NAVIDEA BIOPHARMACEUTICALS : to Present at Upcoming Investor Conferences
09/06 NAVIDEA BIOPHARMACEUTICALS : to Hold Investor Update Call
09/06 NAVIDEA BIOPHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibi..
08/31 NAVIDEA BIOPHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
08/18 NAVIDEA BIOPHARMACEUTICALS : Executes a Term Sheet with Cerveau Technologies to ..
08/11 NAVIDEA BIOPHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security H..
08/11 NAVIDEA BIOPHARMACEUTICALS : Announces 2016 Annual Meeting Results
More news
Sector news : Biotechnology & Medical Research - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/22 Navidea receives $1M in Lymphoseek commercial milestones
09/15 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
09/06 Navidea sells North American rights to Lymphoseek to Cardinal Health for up t..
08/31 Texas court rules in favor of financier, Navidea has 21 days to enter into ac..
08/05 Navidea Biopharmaceuticals (NAVB) Q2 2016 Results - Earnings Call Transcript
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg Chairman
Jed Andrew Latkin Chief Operating & Financial Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
David Colborn Vice President-Clinical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-25.50%145
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results